

# Doseology Announces Management Change

VERNON, BRITISH COLUMBIA, CANADA, March 2, 2022 /EINPresswire.com/ -- Doseology Sciences Inc. ("Doseology" or the "Company") announces the departure of Maryam Marissen as Chief Executive Officer of the Company, effective immediately.

Ralph Olson, Chairman of the Company's board of directors, stated "The Board would like to express its appreciation for Maryam's services to the Company and wishes her well in her future endeavours."



Mr. Olson, who resides in Colorado, has been appointed interim Chief Executive Officer. He is a capital markets veteran with 35 years of experience and has helped raise over \$400,000,000 for both public and private companies in Canada, the United States and Europe. Mr. Olson was previously a Partner, Head of Sales, and Senior Vice President of Cohig and Associates, a boutique broker dealer firm that raised money for small to medium-sized companies. In this role, his responsibilities included managing over 300 registered stock-broker representatives in over 20 offices in the United States.

Mr. Olson's extensive financial expertise and significant experience in mergers and acquisitions will help drive the business forward while navigating this exciting and emerging global sector. With aims to build a strong balance sheet and share price under his leadership, the Company will continue to grow and position its brand as a leading player in the functional fungi and plant-derived drugs sectors.

About Doseology Sciences Inc.

Doseology Sciences Inc. (CSE: MOOD) is building a progressive brand focused on health and wellness through cultivation, extraction and innovative nutraceutical and pharmaceutical products. Doseology aims to make a meaningful impact on the mental health pandemic by utilizing and developing psychedelic and non-psychedelic compounds within the functional fungi and plant-derived drugs markets. With a vertically integrated approach, Doseology intends to

process and distribute products at its facilities in Vernon, British Columbia, in accordance with applicable laws to ensure safe and high-quality production.

For further information contact:

Investor Relations: [investor@doseology.com](mailto:investor@doseology.com)

Media Inquiries: [media@doseology.com](mailto:media@doseology.com)

Telephone: 236-349-0064

Website: [www.doseology.com](http://www.doseology.com)

## Forward Looking Statements

This news release contains statements which constitute “forward-looking information” within the meaning of applicable securities laws. Forward-looking information is often identified by the words “may,” “would,” “could,” “should,” “will,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “expect” or similar expressions. Readers are cautioned that forward-looking information is not based on historical facts but instead reflects the Company’s management’s expectations, estimates or projections concerning the business of the Company’s future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: changes in general economic, business and political conditions, including changes in the financial markets; decreases in the prevailing prices for products in the markets that the Company operates in; adverse changes in applicable laws or adverse changes in the application or enforcement of current laws; regulations and enforcement priorities of governmental authorities; compliance with government regulation and related costs; and other risks described in the Prospectus. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated, or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.

No securities regulatory authority has either approved or disapproved of the contents of this news release. The Company’s securities have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States, or to or for the account or benefit of any person in the

United States, absent registration, or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities in the United States, or in any other jurisdiction in which such offer, solicitation or sale would be unlawful.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

Ralph Olson

Doseology Sciences Inc.

+1 236-349-0064

hello@doseology.com

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

[Other](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/564331076>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 IPD Group, Inc. All Right Reserved.